SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

EDURANT

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved / marketed
Time to market
Already on the market, FDA approved May 20, 2011 (adults); pediatric formulation (EDURANT PED) approved March 15, 2024.
Why 3/10
No hard, dated regulatory catalyst for EDURANT in the next ~12 months, the drug was approved in 2011 (adult) and 2024 (pediatric), and the only near-term dated item is primary completion (2026-08-18) of a 48-patient Phase 2 pediatric roll-over safety study (NCT02494986), which is not a commercial binary, so the score sits at the low end of the approved-product band.
Actionable Insight NEUTRAL

For a JNJ investor, EDURANT is immaterial to the thesis: it is a mature, already-approved HIV pill inside a mega-cap whose value is set by far larger franchises (per JNJ's 10-Q/earnings filings), and no pivotal or regulatory binary is scheduled for this molecule. The only scheduled item to watch is primary completion of the pediatric roll-over study (NCT02494986, est. 2026-08-18); treat any news around it as routine label-support data, not a re-rating event. The more interesting rilpivirine exposure is the long-acting injectable space (cabotegravir + rilpivirine) being developed with ViiV/GSK, but that is a GSK-led program (NCT05917509, Phase 3, completed 2026-04-20), not a JNJ-only catalyst.

Price Chart

Loading chart...

Executive Summary

EDURANT is Johnson & Johnson's (Janssen) rilpivirine HIV tablet, first FDA-approved May 20, 2011, with the pediatric version (EDURANT PED) approved March 15, 2024, per SecBot's FDA catalyst records. It is a mature, marketed product with no pending approval decision or pivotal readout; ongoing JNJ activity is a small Phase 2 pediatric roll-over study (NCT02494986) whose estimated primary-completion date is 2026-08-18. A routine FDA safety-labeling update was recorded March 5, 2026 for the emtricitabine/rilpivirine/tenofovir combination product (hepatitis B exacerbation warning). For JNJ ($262.37 close 2026-08-17; mean analyst PT $272.50 across 22 analysts), EDURANT is a small part of a large portfolio and not a share-price driver.

How It Works

EDURANT (rilpivirine) is a once-daily oral pill for HIV-1. It blocks an enzyme the virus needs to copy its genetic material (reverse transcriptase), so the virus cannot multiply as easily; it is always taken as part of a combination regimen with other antiretrovirals, with food. Rilpivirine is also a component of fixed-dose combination pills and of long-acting injectable regimens used with other HIV drugs.

Trial Status

EDURANT is approved and commercialized. Ongoing JNJ-sponsored work is limited to label-support: a Phase 2 pediatric roll-over study (NCT02494986, Janssen Sciences Ireland UC, 48 patients, active-not-recruiting, est. primary completion 2026-08-18, est. completion 2027-06-30). Separately, a ViiV/GSK-sponsored Phase 3 study of long-acting injectable cabotegravir + rilpivirine every two months versus oral DTG/3TC (NCT05917509, 171 patients) was completed (primary completion 2025-09-16, completion 2026-04-20), relevant to rilpivirine's long-acting future but led by GSK, not JNJ.

The Two-Sided Case

▲ Bull Case4
Long-established approved product: FDA approval catalyst recorded 2011-05-20 (adult) and 2024-03-15 (EDURANT PED pediatric), an approved, marketed drug with a 15-year safety/commercial track record.
Rilpivirine remains strategically relevant in the growing long-acting injectable HIV space: a ViiV/GSK Phase 3 trial of cabotegravir + rilpivirine LA (NCT05917509) completed in 2026, extending the molecule's utility beyond the oral pill.
Recent FDA actions are routine label management, not safety crises for EDURANT itself, the March 2026 safety-labeling update concerned the FTC/RPV/TDF combination product's hepatitis B exacerbation warning, and ongoing label updates (e.g., SPORANOX/CONCERTA) show no EDURANT-specific regulatory problems.
Parent JNJ is a mega-cap with diversified franchises; the drug's sales are stable cash flow within a large, well-covered company (analyst snapshot shows 15 buy + 7 strong buy, 0 sell, mean target $272.50 vs $262.37 close).
▼ Bear Case4
No binary catalysts: EDURANT is already approved (2011/2024) with no pending PDUFA or pivotal readout in the next 12 months, so there is no dated event to drive a re-rating of JNJ.
The only scheduled JNJ-sponsored item is a tiny Phase 2 pediatric roll-over safety study (NCT02494986, 48 patients, est. primary completion 2026-08-18), a routine label-support study that will not move a $260+ stock.
Mature product in a competitive HIV market with ongoing generic/combo erosion risk; FDA safety-labeling updates on rilpivirine-containing combos (hepatitis B exacerbation warning, March 2026) add label burden.
Concentration risk is the reverse of the coin: EDURANT is a negligible fraction of J&J's portfolio, so even positive data has no measurable effect on JNJ shares; insider selling by the CEO (two Form 4 sales on 2026-08-13 totaling ~$32.2M after option exercise) and the CLO (~$4.1M on 2026-08-06) is routine but adds no bullish signal.

Upcoming Catalysts

  • Estimated primary completion (2026-08-18) of Phase 2 pediatric roll-over study NCT02494986, routine safety/continuation data in 48 patients, not a commercial binary.
  • No PDUFA, advisory-committee, or pivotal readout dates are recorded for EDURANT in the next 12 months.
  • Watch GSK-led long-acting injectable (cabotegravir + rilpivirine) commercialization news as the main way rilpivirine exposure could matter, via ViiV, not JNJ.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov